MedTrace Logo

Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer

NCT04724031 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-03-14

No results posted yet for this study

Summary

Real-world clinical outcomes and toxicity data will be evaluated in patients with advanced high grade ovarian cancer who will receive PARP inhibitors.

Conditions

Interventions

DRUG

PARP inhibitor

use at any line of treatment in patients with advanced ovarian cancer

Sponsors & Collaborators

  • Hellenic Cooperative Oncology Group

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2021-06-30
Completion
2023-09-30
FDA Drug
Yes

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04724031 on ClinicalTrials.gov